Botond Timár, MD, PhD

HCEMM-SU Molecular Oncohematology Research Group

Home > Teams > Genomic Instability and Cancer > HCEMM – SU Molecular Oncohematology Research Group > Members > Botond Timár, MD, PhD

Botond Timár, MD, PhD

Botond Timár, MD, Phd

PUBLICATIONS CONTACT

EDUCATION

2005-2009 Board certified pathologistSemmelweis University, Budapest, Hungary
2001-2005 PhD Semmelweis University, School of PhD Studies Pathological sciences, Experimental Oncology
1995-2001 Medical doctor (MD)University of Pécs, Medical SchoolPécs, Hungary

SCIENTIFIC ACTIVITY

2009-Pathologist / assistant professorSemmelweis University, 1stDepartment of Pathology and Experimental Cancer ResearchBudapest, HungaryHematopathology
2011-Consultant hematopathologistKarolinska University Hospital, Department of Pathology and CytologyStockholm, Sweden
2005-Resident in pathology Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary
2003-2005 Research FellowWeill Medical College of Cornell University10021 New York, NY, USA

Publications

42. “Mutational analysis of IgV(H) and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma,”

B. Csernus, B. Timar, Z. Fulop, A. Bognar, A. Szepesi, T. Laszlo, P. Jakso, R. Warnke, L. Kopper, and A. Matolcsy, LEUKEMIA & LYMPHOMA, vol. 45, no. 10, pp. 2105–2110, 2004.

41. “Relationship between the mutational status of V-H genes and pathogenesis of diffuse large B-cell lymphoma in Richter’s syndrome,”

B. Timar, Z. Fulop, B. Csernus, C. Angster, A. Bognar, A. Szepesi, L. Kopper, and A. Matolcsy, LEUKEMIA, vol. 18, no. 2, pp. 326–330, 2004.

40. “Microsatellite instability and hMLH1 promoter hypermethyl ation in Richter’s transformation of chronic lymphocytic leukemia,”

Z. Fulop, B. Csernus, B. Timar, A. Szepesi, and A. Matolcsy, LEUKEMIA, vol. 17, no. 2, pp. 411–415, 2003.

39. “Genetic instability is associated with histological transformation of follicle center lymphoma,”

M. Nagy, M. Balazs, Z. Adam, Z. Petko, B. Timar, Z. Szereday, T. Laszlo, R. A. Warnke, and A. Matolcsy, LEUKEMIA, vol. 14, no. 12, pp. 2142–2148, 2000.

38. “Új lehetőség a krónikus myeloproliferativ betegségek diagnosztikájában,”

H. Rajnai, C. Bödör, L. Reiniger, B. Tímár, B. Csernus, Á. Szepesi, J. Csomor, and A. Matolcsy, ORVOSI HETILAP, vol. 147, no. 45, pp. 2175–2179, 2006.

37. “Prognostic significance and detection of the internal tandem duplication of the FLT3 gene in acute myeloid leukemia,”

E. Gagyi, E. Horváth, C. Bödör, B. Timár, A. Matolcsy, and Z. Pávai, ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRIOLOGY, vol. 47, no. 4, pp. 331–337, 2006.

36. “BCR-ABL mRNS expressziós szintek valős idejű kvantitatív PCR-rel történő követése krónikus myeloid leukaemiás betegek esetében,”

C. Bödör, H. Rajnai, B. Tímár, J. Csomor, and A. Matolcsy, HEMATOLÓGIA-TRANSZFUZIOLÓGIA, vol. 40, no. 1, pp. 7–14, 2007.

35. “Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression,”

E. Gagyi, Z. Balogh, C. Bödör, B. Timár, L. Reiniger, L. Deák, J. Csomor, B. Csernus, A. Szepesi, and A. Matolcsy, HAEMATOLOGICA, vol. 93, no. 12, pp. 1822–1828, 2008.

34. “Praenatalis ultrahangvizsgálattal felismert magzati craniopharyngeoma (másodközlés magyar nyelven),”

J. Joó, J. J. Rigó, Z. Sápi, and B. Tímár, MAGYAR NŐORVOSOK LAPJA, vol. 71, no. 4, pp. 177–180, 2008.

33. “Foetal craniopharyngioma diagnosed by prenatal ultrasonography and confirmed by histopathological examination,”

J. Joó, J. J. Rigó, Z. Sápi, and B. Tímár, PRENATAL DIAGNOSIS, vol. 29, no. 2, pp. 160–163, 2009.

32. “Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma,”

J. Csomor, I. Kaszas, B. Kollar, L. Pajor, Z. Egyhazi, S. Fekete, M. Egyed, and B. Timar, PATHOLOGY AND ONCOLOGY RESEARCH, vol. 14, no. 3, pp. 281–284, 2008.

31. “BCL-2 negative follicular lymphoma is associated with somatic hypermutationof the IGV(H) genes and aberrant somatic hypermutation,”

E. Gagyi, Z. Balogh, C. Bodor, B. Timar, L. Reiniger, L. Deak, J. Csomor, B. Csernus, A. Szepesi, and A. Matolcsy, ANNALS OF ONCOLOGY, vol. 19, no. Suppl. 4, pp. 200–200, 2008.

30. “ROR1 expression is not a unique marker of CLL,”

G. Barna, R. Mihalik, B. Timar, J. Tombol, Z. Csende, A. Sebestyen, C. Bodor, B. Csernus, L. Reiniger, I. Petak, and A. Matolcsy, HEMATOLOGICAL ONCOLOGY, vol. 29, no. 1, pp. 17–21, 2011.

29. “Intravascular large B-cell lymphoma: clinicopathological study of seven cases,”

A. Szepesi, N. Eros, B. Timar, B. Horvath, A. Matolcsy, and J. Csomor, EJC SUPPLEMENTS, vol. 8, no. 4, p. 32, 2010.

28. “ROR1 EXPRESSION IS NOT A UNIQUE MARKER OF CLL,”

G. Barna, R. Mihalik, B. Timar, Z. Csende, A. Sebestyen, J. Tombol, C. Bodor, B. Csernus, and A. Matolcsy, CYTOMETRY PART B-CLINICAL CYTOMETRY, vol. 78B, no. 6, pp. 436–436, 2010.

27. “A nationwide study of ‘in situ’ follicular lymphoma in Hungary,”

B. Timar, J. Csomor, H. Rajnai, T. Micsik, and A. Matolcsy, VIRCHOWS ARCHIV, vol. 459, no. Suppl. 1, pp. S34–S34, 2011.

26. “Activity and complexes of mTOR in diffuse large B-cell lymphomas-a tissue microarray study.,”

A. Sebestyen, T. Sticz, A. Mark, M. Hajdu, B. Timar, K. Nemes, N. Nagy, Z. Varadi, and L. Kopper, MODERN PATHOLOGY, vol. 25, no. 12, pp. 1623–1628, 2012.

25. “Pseudomembranous colitis (PMC) epidemic in the autopsy room,”

T. Micsik, B. Timar, L. Fonyad, B. Csernus, G. Princz, and J. Csomor, VIRCHOWS ARCHIV, vol. 459, no. Suppl. 1, pp. S304–S304, 2011.

24. “Intravascular large B-cell lymphoma,”

J. Csomor, L. Fonyad, L. Reiniger, and B. Timar, BLOOD REVIEWS, vol. 21, no. Suppl. 1, pp. S128–S128, 2007.

23. “Clinicopathological features of plasmablastic lymphoma in AIDS patients,”

J. Csomor, B. Timar, S. Fekete, and D. Banhegyi, BLOOD REVIEWS, vol. 21, no. 1, pp. S128–S129, 2007.

22. “The alternative NF-kB pathway is active in the majority of diffuse large B-cell lymphomas,”

B. Timar, A. Chadburn, D. Knowles, and E. Cesarman, LABORATORY INVESTIGATION, vol. 86, no. 1, p. 248A–248A, 2006.

21. “The alternative NF-kB pathway is active in the majority of diffuse large B-cell lymphomas,”

B. Timar, A. Chadburn, D. Knowles, and E. Cesarman, MODERN PATHOLOGY, vol. 19, no. 1, p. 248A–248A, 2006.

20. “Activation of classical and alternative nuclear factor-kappaB (NF-kB) pathways in diffuse large B-cell lymphomas.,”

B. Timar, A. Chadburn, D. Knowles, and E. Cesarman, BLOOD, vol. 104, no. 11, p. 12A–13A, 2004.

19. “Két ciklus kemoimmunoterápia után végzett interim FDG-PET prognosztikai értéke diffúz nagy B-sejtes lymphoma esetén: a vizuális és szemikvantitatív értékelés összehasonlítása,”

T. Györke, T. Tőkés, A. Lantos, C. Korom, J. Gyebnár, I. Garai, Z. Tóth, Á. Szepesi, B. Timár, J. Demeter, Z. Nagy, E. Sári, Á. Illés, L. Gergely, A. Sipos, G.Mikala, and T. Masszi, MAGYAR RADIOLÓGIA, vol. 87, no. 1, pp. 43–55, 2013.

18. “Philadelphia-negatív krónikus myeloproliferatív neoplasma mellett kialakult hajas sejtes leukaemiavariáns idős férfi betegben,”

E. Sári, I. Tárkányi, E. Farczádi, B. Tímár, Z. Nagy, and J. Demeter, HEMATOLÓGIA-TRANSZFUZIOLÓGIA, vol. 46, no. Suppl. 1, pp. 105–106, 2013.

17. “The prognostic role of interim FDG-PET in diffuse large B-cell lymphoma,”

T. Györke, T. Tőkés, A. Lantos, C. Korom, J. Gyebnár, I. Garai, Z. Tóth, Á. Szepesi, B. Timár, J. Demeter, Z. Nagy, E. Sári, Á. Illés, L. Gergely, A. Sipos, G. Mikala, and T. Masszi, NUCLEAR MEDICINE REVIEW: CENTRAL AND EASTERN EUROPE, vol. 16, no. Suppl. A, p. A10, 2013.

16. “CD8 pozitív mycosis fungoides esete,”

N. Gyöngyösi, B. Timár, J. Hársing, J. Csomor, Á. Szepesi, A. Matolcsy, S. Kárpáti, and M. Marschalkó, BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE, vol. 91, no. 1, pp. 48–51, 2015.

15. “Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides,”

D. Marosvari, V. Teglasi, I. Csala, M. Marschalko, C. Bodor, B. Timar, J. Csomor, J. Harsing, and L. Reiniger, PATHOLOGY AND ONCOLOGY RESEARCH, vol. 21, no. 3, pp. 821–825, 2015.

14. “PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.,”

M. Boi, A. Rinaldi, I. Kwee, P. Bonetti, M. Todaro, F. Tabbò, R. Piva, P. Rancoita, A. Matolcsy, B. Timar, T. Tousseyn, S. Rodríguez-Pinilla, M. Piris, S. Beà, E. Campo, G. Bhagat, S. Swerdlow, A. Rosenwald, M. Ponzoni, K. Young, P. Piccaluga, R. Dummer, S. Pileri, E. Zucca, G. Inghirami, and F. Bertoni, BLOOD, vol. 122, no. 15, pp. 2683–2693, 2013.

13. “The effect of microenvironmental factors on the development of myeloma cells,”

A. Mark, G. Varga, B. Timar, C. Kriston, O. Szabo, L. Deak, A. Matolcsy, and G. Barna, HEMATOLOGICAL ONCOLOGY, vol. 35, no. 4, pp. 741–745, 2017.

12. “Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score.,”

N. Tekin, N. Omidvar, T. Morris, P. Conget, F. Bruna, B. Timar, E. Gagyi, R. Basak, O. Naik, C. Auewarakul, N. Sritana, D. Levy, J. Cerci, S. Bydlowski, J. Pereira, M. Dimamay, F. Natividad, J. Chung, N. Belder, I. Kuzu, D. Paez, M. Dondi, R. Carr, H. Ozdag, and R. Padua, ONCOTARGET, vol. 7, no. 50, pp. 83319–83329, 2016.

11. “The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.,”

R. Carr, H. Ozdag, N. Tekin, T.Morris, P. Conget, F. Bruna, B. Timar, E. Gagyi, R. Basak, O. Naik, C. Auewarakul, N. Srithana, M. Dimamay, F. Natividad, J. Chung, N. Belder, I. Kuzu, N. Omidvar, D. Paez, and R. Padua, LEUKEMIA & LYMPHOMA, vol. 58, no. 5, pp. 1178–1183, 2017.

10. “A plazmasejtes mielóma genetikai sajátosságai és patológiája,”

B. Tímár, MAGYAR ONKOLÓGIA, vol. 60, no. 2, pp. 145–153, 2016

9. “MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT, 12 CASES AND REVIEW OF THE LITERATURE,”

G. Varga, G. Mikala, L. Gopcsa, Z. Csukly, P. Remenyi, G. Szombath, A. Masszi, H. Andrikovics, G. Balazs, B. Timar, and T. Masszi, HAEMATOLOGICA, vol.102, no. Suppl. 2, pp. 787–788, 2017.

8. “A limfoplazmocitas limfoma/Waldenstrom-makroglobulinemia patologiaja es genetikaja.,”

B. Timar, MAGYAR ONKOLÓGIA, vol. 61, no. 1, pp. 6–11, 2017.

7. “Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms,”

A. Gango, R. Mozes, Z. Boha, B. Kajtar, B. Timar, P. Kiraly, R. Kiss, V. Fesus, N. Nagy, J. Demeter, G. Korosmezey, Z. Borbenyi, I. Marton, A. Szoke, T. Masszi, P. Farkas, J. Varkonyi, M. Plander, E. Posfai, M. Egyed, K. Pal, G. Radvanyi, A. Hamed, J. Csomor, A. Matolcsy, D. Alpar, and C. Bodor, LEUKEMIA RESEARCH, vol. 65, pp. 42–48, 2018.

6. “Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature,”

G. Varga, G. Mikala, L. Gopcsa, Z. Csukly, S. Kollai, G. Balazs, B. Timar, N. Wohner, L. Horvath, G. Szombath, P. Farkas, and T. Masszi, JOURNAL OF ONCOLOGY, vol. 2018, 2018.

5. “Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms,”

R. Mózes, A. Gángó, A. Sulák, L. Vida, L. Reiniger, B. Timár, T. Krenács, H. Alizadeh, T. Masszi, J. Gaál-Weisinger, J. Demeter, J. Csomor, A. Matolcsy, B. Kajtár, and C. Bödör, PATHOLOGY, vol. 51, no. 3, pp. 301–307, 2019.

4. “Központi idegrendszeri érintettség myelomában: áttekintés 13 eset tükrében,”

G. Varga, G. Mikala, L. Gopcsa, S. Kollai, B. Timár, G. Balázs, and T. Masszi, MAGYAR BELORVOSI ARCHIVUM, vol. 71, no. 2, pp. 80–87, 2018.

3. “Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System,”

N. Omidvar, N. Tekin, P. Conget, F. Bruna, B. Timar, E. Gagyi, R. Basak, C. Auewarakul, N. Sritana, J. J. Cerci, M. P. Dimamay, T. Gyorke, F. Redondo, R. Nair, C. Gorospe, D. Paez, S. Fanti, H. Ozdag, R. A. Padua, and R. Carr, ACTA HAEMATOLOGICA, vol. 143, no. 6, pp. 600–602, 2020.

2. “Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification,”

L. Saft, B. Timar, and A. Porwit, JOURNAL OF HEMATOPATHOLOGY, vol. 13, pp. 79–88, 2020

1. “Grade I, II and III Follicular Lymphomas Express Ig VH Genes with Different Patterns of Somatic Mutation,”

B. Csernus, B. Timár, Z. Fülöp, and A. Matolcsy, PATHOLOGY AND ONCOLOGY RESEARCH, vol. 2020, 2020.

HCEMM-SU Molecular Oncohematology Research Group

Botond Timár, MD, PhD

Botond Timár, MD, Phd

EDUCATION

SCIENTIFIC ACTIVITY

Publications

42. “Mutational analysis of IgV(H) and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma,”

41. “Relationship between the mutational status of V-H genes and pathogenesis of diffuse large B-cell lymphoma in Richter’s syndrome,”

40. “Microsatellite instability and hMLH1 promoter hypermethyl ation in Richter’s transformation of chronic lymphocytic leukemia,”

39. “Genetic instability is associated with histological transformation of follicle center lymphoma,”

38. “Új lehetőség a krónikus myeloproliferativ betegségek diagnosztikájában,”

37. “Prognostic significance and detection of the internal tandem duplication of the FLT3 gene in acute myeloid leukemia,”

36. “BCR-ABL mRNS expressziós szintek valős idejű kvantitatív PCR-rel történő követése krónikus myeloid leukaemiás betegek esetében,”

35. “Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression,”

34. “Praenatalis ultrahangvizsgálattal felismert magzati craniopharyngeoma (másodközlés magyar nyelven),”

33. “Foetal craniopharyngioma diagnosed by prenatal ultrasonography and confirmed by histopathological examination,”

32. “Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma,”

31. “BCL-2 negative follicular lymphoma is associated with somatic hypermutationof the IGV(H) genes and aberrant somatic hypermutation,”

30. “ROR1 expression is not a unique marker of CLL,”

29. “Intravascular large B-cell lymphoma: clinicopathological study of seven cases,”

28. “ROR1 EXPRESSION IS NOT A UNIQUE MARKER OF CLL,”

27. “A nationwide study of ‘in situ’ follicular lymphoma in Hungary,”

26. “Activity and complexes of mTOR in diffuse large B-cell lymphomas-a tissue microarray study.,”

25. “Pseudomembranous colitis (PMC) epidemic in the autopsy room,”

24. “Intravascular large B-cell lymphoma,”

23. “Clinicopathological features of plasmablastic lymphoma in AIDS patients,”

22. “The alternative NF-kB pathway is active in the majority of diffuse large B-cell lymphomas,”

21. “The alternative NF-kB pathway is active in the majority of diffuse large B-cell lymphomas,”

20. “Activation of classical and alternative nuclear factor-kappaB (NF-kB) pathways in diffuse large B-cell lymphomas.,”

19. “Két ciklus kemoimmunoterápia után végzett interim FDG-PET prognosztikai értéke diffúz nagy B-sejtes lymphoma esetén: a vizuális és szemikvantitatív értékelés összehasonlítása,”

18. “Philadelphia-negatív krónikus myeloproliferatív neoplasma mellett kialakult hajas sejtes leukaemiavariáns idős férfi betegben,”

17. “The prognostic role of interim FDG-PET in diffuse large B-cell lymphoma,”

16. “CD8 pozitív mycosis fungoides esete,”

15. “Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides,”

14. “PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.,”

13. “The effect of microenvironmental factors on the development of myeloma cells,”

12. “Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score.,”

11. “The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.,”

10. “A plazmasejtes mielóma genetikai sajátosságai és patológiája,”

9. “MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT, 12 CASES AND REVIEW OF THE LITERATURE,”

8. “A limfoplazmocitas limfoma/Waldenstrom-makroglobulinemia patologiaja es genetikaja.,”

7. “Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms,”

6. “Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature,”

5. “Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms,”

4. “Központi idegrendszeri érintettség myelomában: áttekintés 13 eset tükrében,”

3. “Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System,”

2. “Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification,”

1. “Grade I, II and III Follicular Lymphomas Express Ig VH Genes with Different Patterns of Somatic Mutation,”

Awards

Consortium

About HCEMM

Internal Policies

Contact Info